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Abstract
The biological mechanisms behind the development of pulmonary hypertension in the setting of left heart failure (HF-PH), including
combined pre- and post-capillary pulmonary hypertension (Cpc-PH), remains unclear. This study aimed to use candidate poly-
morphisms in nitric oxide synthase (NOS) genes to explore the role of NOS in HF-PH. DNA samples from 118 patients with
HF-PH were genotyped for the NOS3 rs1799983 and NOS2 rs3730017 polymorphisms. A multiple regression model was used to
compare hemodynamic measurements between genotype groups. Patients with the T/T genotype at rs1799983 possessed a nearly
10mmHg increased transpulmonary gradient (TPG) compared to those with other genotypes (P¼ 0.006). This finding was
replicated in an independent cohort of 94 HF-PH patients (P¼ 0.005). However, when tested in a cohort of 162 pre-capillary
pulmonary arterial hypertension patients, no association was observed. In a combined analysis of both HF-PH cohorts, mean
pulmonary artery pressure (mPAP), diastolic pulmonary gradient (DPG), and CpcPH status were also associated with rs1799983
genotype (P¼ 0.005, P¼ 0.03, and P¼ 0.02, respectively). In patients with HF-PH, the NOS3 rs1799983 polymorphism is associated
with TPG, and potentially mPAP and DPG as well. These findings suggest that endothelial NOS (encoded by NOS3) may be involved
in the pulmonary vascular remodeling observed in Cpc-PH and warrants further study.
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Pulmonary hypertension (PH) is estimated to occur in
50–80% of patients with left heart failure (HF).1,2 PH stem-
ming from left heart disease, or World Health Organization
(WHO) Group 2 PH, is defined as a mean pulmonary artery
pressure (mPAP) 25mmHg and a pulmonary artery wedge
pressure (PAWP) 15mmHg. The underlying mechanism
for development of Group 2 PH is thought to be related
to pulmonary venous hypertension – passive increases in
pulmonary venous pressures transmitted from increased
left atrial pressure. However, a significant number of
patients have a mPAP disproportionate to that expected
from their left HF, known as combined pre- and post-
capillary PH (Cpc-PH). The addition of PH to a diagnosis
of left heart failure (HF-PH) confers an increased risk of
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mortality, but whether Cpc-PH confers additional mortality
risk is controversial.3–6
The development of Cpc-PH (or reactive PH), indicated
by diastolic pulmonary gradient (DPG) 7mmHg (or trans-
pulmonary gradient [TPG] 12mmHg), is associated with
pulmonary vascular remodeling, likely from chronic pres-
sure-induced injury. The biological mechanisms behind
this remodeling are unclear, but are thought to include
pulmonary vasoconstriction, fibrosis, smooth muscle cell
proliferation, and endothelial dysfunction.7–9 Central to
endothelial dysfunction in PH is an imbalance of the vaso-
dilator nitric oxide (NO) and the vasoconstrictor endothe-
lin-1.10 In addition to its vasodilatory properties, NO also
has antiproliferative and antioxidant effects, and decreases
platelet aggregation.11,12 Thus, a decreased NO availability
can affect multiple biological pathways in PH.
Our hypothesis was that genetic polymorphisms affecting
baseline nitric oxide synthase (NOS) enzyme function would
lead to increased PH severity in patients with left HF. The
aim of this study was to use candidate polymorphisms in
NOS genes to explore the role of NOS in PH severity asso-
ciated with left HF.
Methods
Patient populations
All patients provided written, informed consent for partici-
pation and recruitment protocols were approved by the
institutional review boards at each respective institution.
The discovery cohort included heart failure with preserved
ejection fraction (HFpEF) and heart failure with reduced
ejection fraction (HFrEF) patients recruited from cardi-
ology and pulmonology clinics at the University of Illinois
at Chicago (UIC). HF-PH was confirmed in individuals by a
documented mPAP 25mmHg and PAWP 15mmHg as
measured by right heart catheterization (RHC), without
echocardiographic evidence of moderate or severe valvular
disease. To permit the potential replication of associations
found in the discovery cohort, an independent HF-PH val-
idation population was also included. This cohort com-
prised individuals from Northwestern University and
Stanford University using identical criteria for HF-PH. To
compare potential associations with other forms of PH, a
cohort of patients with pulmonary arterial hypertension
(pre-capillary or WHO Group 1 PH) recruited from UIC
was also analyzed. Group 1 PH was defined as mPAP
25mmHg and PAWP <15mmHg as measured by RHC,
with no history of pulmonary embolism or diseases that are
associated with other forms of PH.
Genotyping
The two candidate enzymes included in this study were indu-
cible nitric oxide synthase (iNOS) and endothelial nitric
oxide synthase (eNOS). The single nucleotide polymorphism
(SNP) most likely to affect gene expression was chosen for
both NOS2 and NOS3, the genes that encode iNOS and
eNOS, respectively. For NOS2, the non-synonymous SNP
rs3730017 (Arg221Trp) was chosen because in silico ana-
lyses using SIFT13 and Polyphen-214 predict that the variant
is damaging to the protein structure. For NOS3, the well-
studied non-synonymous SNP rs1799983 was chosen, which
has been previously associated with alterations of endogen-
ous nitric oxide (NO) production.15,16
DNA from individuals was isolated from either whole
blood (UIC and Stanford) or buccal cells (Northwestern).
Genotyping of rs1799983 and rs3730017 was completed
using pyrosequencing on the HS96 platform (Qiagen,
Valencia, CA, USA).
Statistical analysis
Comparisons of genotype frequencies between HF-PH
patients and control HF patients were completed using a
Chi-square test. To assess associations between severity of
PH and candidate SNPs, mPAP, PAWP, TPG, DPG, car-
diac output (CO), and pulmonary vascular resistance (PVR)
were compared by genotype in the discovery cohort using a
multiple regression model, adjusting for the following cov-
ariates: age; sex; race; systolic blood pressure; and diastolic
blood pressure. Genotype effects were analyzed using a
recessive genetic model (A/AþA/a vs. a/a) for rs1799983
and a dominant model (A/A vs. A/aþ a/a) for rs3730017,
due to the very small number of homozygous variant sub-
jects. Identical regression analyses were also completed with
rs1799983 in the HF-PH validation and PAH cohorts
(except for DPG, which was not available), adjusting for
the same covariates. Secondarily, a combined analysis
(including both discovery and validation HF-PH cohorts)
was completed in an attempt to leverage increased statistical
power to detect associations with smaller effect sizes, using
an identical regression as described above. In addition, the
genotype frequencies of rs1799983 and rs3730017 were com-
pared under the same genetic models as above in patients
with and without CpcPH (defined as TPG 12mmHg or
DPG 7mmHg), as well as between patients with HFpEF
(EF 50%) and HFrEF (EF< 50%) using a two-sample
unpaired t-test. A sensitivity analysis was also completed
with rs1799983 in the combined cohort to test the same
associations by race (patients of African descent and
patients of European/Latino descent). All statistical ana-
lyses were performed using R statistical software version
3.4.0 (R Foundation for Statistical Computing).
Results
The discovery and validation HF-PH cohorts were similar,
except for racial distribution (Table 1). As expected, the
PAH cohort differed in age, race, and hemodynamic profile
due to the different presentation of the disease as well as
the gender bias for PAH. All genotype results were in
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Hardy-Weinberg equilibrium, and minor allele frequency in
all samples genotyped for rs1799983 and rs3730017 were
0.26 and 0.04, respectively. This corresponds with frequen-
cies observed in populations of European and African des-
cent within the NCBI dbSNP database.
In the discovery cohort, patients with the variant T/T
genotype at rs1799983 had a mean TPG that was
9.5mmHg greater than patients with other genotypes
(Padj¼ 0.0059; Fig. 1a). This association between TPG and
rs1799983 was also observed in the validation cohort, with T
homozygotes possessing a mean TPG that was 12mmHg
higher (Padj¼ 0.0047; Fig. 2). There was also a trend
toward increased mean DPG values (3.5mmHg higher) in
the discovery cohort (Padj¼ 0.082), but no association in the
validation cohort (4.3mmHg higher, Padj¼ 0.29; Figs. 1a
and 2). In the validation cohort, T/T genotype was asso-
ciated with a 12.2mmHg higher mPAP (Padj¼ 0.026) and
a 5.9 Wood Unit (WU) increase in mean PVR (P¼ 0.0008;
Fig. 2). No associations were observed in either cohort
between rs1799983 and PAWP or CO (Figs. 1a and 2).
Likewise, we found no associations between rs3730017 and
any of the analyzed hemodynamic measures (Fig. 1b).
Second, we conducted a combined analysis including
both the discovery and validation cohorts. In addition to a
much stronger association with TPG (Padj¼ 3.0 10–5), we
found that patients with the variant T/T genotype had an
average mPAP that was 10.4mmHg greater (Padj¼ 0.0054),
a mean DPG that was 4.2mmHg higher (Padj¼ 0.031), and
a mean PVR 3.0 WU higher (Padj¼ 0.0023) than other
genotypes. Again, no associations were observed with
PAWP and CO (Fig. 3a). Consistent with previous findings
in the individual cohorts, we found no association between
rs3730017 and any measured hemodynamic values (Fig. 3b).
Additional analyses were undertaken to further explore
associations between rs1799983 and PH severity. The fre-
quency of the T/T genotype was compared in patients
with and without CpcPH (defined as TPG 12mmHg or
DPG 7mmHg, Table 2) in the combined HF-PH cohort.
The variant T/T genotype was significantly more common in
CpcPH patients than patients without CpcPH (8.8% vs
1.1%, P¼ 0.015). Genotype frequencies were also compared
between HFpEF and HFrEF patients, but no differences
were found (4.4% vs 4.1%, P¼ 0.93). To assess whether
the observed associations with rs1799983 are similar across
other types of PH or exclusive to HF-PH, we analyzed an
independent cohort of WHO Group 1 PAH patients. We
found no association between the SNP and TPG, mPAP,
PAWP, or PVR (Fig. 4).
As a sensitivity analysis, rs1799983 was analyzed within
the combined cohort by race. Associations with TPG
(Padj¼ 5.7 10–5), DPG (Padj¼ 0.0057), and mPAP
(Padj¼ 0.0046) were similar in those of European and
Latino ancestry as in the overall combined cohort (Suppl.
Fig. S1a). In African Americans, similar associations with
TPG were also detected, but only trended toward signifi-
cance (Padj¼ 0.077), but PVR remained significantly asso-
ciated (Padj¼ 0.001). DPG and mPAP were not significantly
associated in the African American subset (Suppl. Fig. S1b).
Discussion
The current study demonstrates that rs1799983, a putatively
functional SNP within eNOS, is associated with TPG in HF-
PH patients. The association is present in two independent
patient cohorts with varying racial compositions. In add-
ition, DPG, PVR, and mPAP may also be associated with
rs1799983 in this patient population, based on associations
observed in a combined analysis of both HF-PH cohorts.
Further, we found that CpcPH patients were more likely to
carry the rs1799983 variant T/T genotype. The lack of simi-
lar hemodynamic associations in patients with PAH sug-
gests that these associations may be specific to HF-PH.
This claim is further supported by previous research indicat-
ing that rs1799983 is also not associated with Group 3 PH
(PH due to lung disease or hypoxia).17
Rs1799983 is a non-synonymous SNP in NOS3 (the gene
encoding eNOS) that leads to an amino acid substitution
(Glu298Asp) and has been associated with decreased base-
line production of NO in humans.15 The aspartate substitu-
tion (resulting from the T allele) in eNOS is thought to cause
cleavage of the enzyme, likely shortening its half-life, and
may also effect the enzyme’s secondary structure.16 The T
allele at this SNP has been previously associated with
increased risk of end-stage renal disease, dilated cardiomy-
opathy, and decreased survival in patients with HFrEF.18–20








Mean age (years) 59.9 11.7 64.5 11.5 52.8 15.5
Female (%) 47.5 48.9 79.3
Race
European ancestry (%) 16.1 52.1 84.4
Latino ancestry (%) 9.3 34.0 10.1
African ancestry (%) 74.5 13.8 1.7
HFpEF (EF 50%) (%) 15.0 98.9 N/A
Mean PASP (mmHg) 59.5 16.7 59.5 17.9 N/A
Mean PADP (mmHg) 27.6 7.3 27.9 8.2 N/A
mPAP (mmHg) 39.1 9.9 38.4 10.7 45.8 14.5
Mean PAWP (mmHg) 24.9 8.1 23.7 7.0 8.6 4.8
Mean TPG (mmHg) 14.2 9.6 14.8 9.7 37.4 16.1
Mean DPG (mmHg) 4.2 5.3 4.3 6.8 N/A




All values are presented as mean SD unless otherwise stated.
HFpEF, heart failure with preserved ejection fraction; PASP, pulmonary artery
systolic pressure; PADP, pulmonary artery diastolic pressure; mPAP, mean pul-
monary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pul-
monary vascular resistance; TPG, transpulmonary gradient; DPG, diastolic
pressure gradient; N/A, not available.
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While associations between the variant T allele and
increased systemic blood pressure have previously been
both reported and refuted,21–24 we did not find associations
with systemic blood pressure in either cohort. However, to
our knowledge, this is the first report of an association with
rs1799983 and any type of PH.
Elevated mPAP, PVR, TPG, and DPG have all been
associated with decreased survival in patients with left
HF.3,4 This is likely because, to some extent, they are all
linked to Cpc-PH. While the exact definition of Cpc-PH
has evolved over the past few years (from TPG 12 to
DPG 7 to DPG 7 and/or PVR> 3 WU) the definitions
consistently include measurements that increase definitively
with the development of pulmonary vascular remodeling.7
This remodeling is thought to be the cause of the increased
mortality risk some have observed in CpcPH patients.4,25
Because of its previous connection with many other cardio-
vascular diseases and the established role of NO in vascular
remodeling, the observed connection between rs1799983 and
markers of worsening vascular remodeling is biologically
reasonable.
Vasoconstriction plays a key role in TPG changes within
the pulmonary circuit.7 Thus, it seems plausible that TPG
would have one of the strongest association with rs1799983.
The increased PVR observed with T/T patients in the com-
bined cohort supports this concept. The potential U-shaped
survival curve previously associated with DPG4 could
explain the weaker association we observed with DPG.
The significantly larger sample size in the combined cohort
likely provided the improved power to detect this weaker
association. The fact that PAWP, an estimator of left
atrial pressure, was not associated with rs1799983 genotype
Fig. 1. Mean hemodynamic measurements of HF-PH discovery cohort by (a) rs1799983 and (b) rs3730017 genotype. *Padj 0.05.
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in any analysis seems to imply that the degree of pulmonary
venous hypertension (stemming from left HF) is not affected
by eNOS genetic variation. In addition, there was no differ-
ence in rs1799983 genotype frequency between HFpEF and
HFrEF patients suggesting that the genetic effect is likely
not driven by HF subtype or severity. These data further
support the interpretation that patients with variation at
rs1799983 (and likely with a baseline NO imbalance) may
be at greater risk for developing pulmonary vascular
remodeling, possibly via increased susceptibility to endothe-
lial dysfunction.
Rs3730017 is a non-synonymous SNP in NOS2 (the gene
encoding inducible NOS) that leads to an amino acid sub-
stitution (Arg298Trp), calculated in silico by Polyphen-2
(http://genetics.bwh.harvard.edu/pph2/) to be possibly
damaging. This SNP is not well-studied, likely because its
minor allele frequency (MAF)< 3% in Europeans.
However, with a MAF¼ 20–24% in those of African des-
cent, it was deemed a reasonable candidate to investigate in
the predominantly African American discovery cohort. We
found no association between rs3730017 and any hemo-
dynamic measurement tested. While these findings indicate
that this specific SNP is unlikely to be associated with PH
severity in HF, it cannot rule out NOS2 as a potential
contributor.
Importantly, associations between rs1799983 and TPG
were observed in both a predominantly African American
cohort (discovery) and a predominantly European
American cohort (validation). It is not surprising that the
association was stronger in the European American cohort
because the MAF of rs1799983 is much higher those of
European descent (MAF¼ 33–34%) than in those of
African descent (MAF¼ 7–16%; per NCBI: https://www.
ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs¼1799983).
Although race was adjusted for in all regression analyses, an
additional sensitivity analysis was conducted, re-analyzing
hemodynamic associations by race to assess potential con-
founding with rs1799983 associations that could be due to
population stratification. In both race groups, the mean
TPG, mPAP, and DPG were higher in T/T homozygotes,
with the associations strongly significant in European
Americans and TPG trending toward significance in
African Americans. However, with our observed TPG
values, ¼ 0.05, and MAF¼ 16%, we would require a
sample size of African American individuals slightly larger
(n¼ 108) than were analyzed (n¼ 101) to achieve a power
(1 -) of 80%. In those of European ancestry (MAF¼ 33%),
a much smaller sample size (n¼ 35) is needed. Thus, it is
likely that we were slightly underpowered to detect an effect
in TPG in the African American subset.
This study has several limitations. First, it used a small
sample size of patients with multiple types of HF; thus, we
are unable to assess whether the described eNOS associ-
ations are more prominent in a specific HF subtype.
However, little is known regarding the etiology of CpcPH;
thus, it is unknown at this point whether HF subtype is a
potential confounder in these analyses. However, the fact
that this association was detected in both a primarily
HFrEF cohort (discovery) and a primarily HFpEF cohort
(validation) suggests that this effect is independent of HF
subtype. Second, comprehensive drug histories were not
available on many of the patients (47%), so the potential
confounding from drugs that could affect pulmonary vascu-
lar pressure could not be determined. However, from the
data available, use of PH-specific therapy (phosphodies-
terase-5 inhibitors, prostacyclins, or endothelin-1 receptor
antagonists) was low (12%). Next, because these data
were from cohorts assessed at a single point in time, we
were unable to examine the role of rs1799983 in the devel-
opment of PH. Further, biological validation by measuring
Fig. 2. Mean hemodynamic measurements of HF-PH validation cohort by rs1799983 genotype. *Padj 0.05; yPadj< 0.001.
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Fig. 3. Mean hemodynamic measurements of the combined discovery and validation HF-PH cohorts by (a) rs1799983 and (b) rs3730017
genotype. *Padj 0.05; yPadj< 0.001.
Table 2. Characteristics of the combined patient cohorts by CpcPH
status.
Characteristic CpcPH (n¼ 118) No CpcPH (n¼ 93)
Mean age (years) 63.0 11.0 60.8 12.8
Female (%) 48.3 57.0
Race
European ancestry (%) 37.3 25.8
Latino ancestry (%) 16.1 25.8
African ancestry (%) 46.6 48.4
HFpEF (EF 50%) (%) 63.8 54.5
Mean PASP (mmHg) 67.0 17.7 50.2 11.1
Mean PADP (mmHg) 29.3 7.8 25.8 7.2
(continued)
Table 2. Continued
Characteristic CpcPH (n¼ 118) No CpcPH (n¼ 93)
mPAP (mmHg) 42.9 10.4 33.8 7.4
Mean PAWP (mmHg) 22.4 7.0 27.0 7.8
Mean TPG (mmHg) 20.5 8.7 6.8 3.0
Mean DPG (mmHg) 7.2 6.7 0.7 1.4
Mean PVR (WU) 5.2 4.2 2.3 1.2
All values are presented as mean SD unless otherwise stated.
HFpEF, heart failure with preserved ejection fraction; PASP, pulmonary artery
systolic pressure; PADP, pulmonary artery diastolic pressure; mPAP, mean pul-
monary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pul-
monary vascular resistance; TPG, transpulmonary gradient; DPG, diastolic
pressure gradient; N/A, not available.
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NO generation would strengthen the proposed link between
rs1799983 and NO signaling. However, biological samples
appropriate for NO estimation were not available in either
cohort. Lastly, functional validation of the reported SNP
associations has yet to be tested and is necessary to confirm
that rs1799983 plays a causative role in PH severity.
Patients with Cpc-PH are known to undergo pulmonary
vascular remodeling, including endothelial dysfunction.8,10
Our results suggest that genetic variability affecting the NO
signaling pathway, potentially by causing abnormal pul-
monary endothelial dysfunction, may influence susceptibil-
ity to CpcPH. Further study of NO signaling in HF-PH may
provide insight into PH pathogenesis in patients with left
HF and could potentially lead to new therapeutic targets
for the disease.
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